[Studies on the bioavailability of the individual components from a combination of dilazep and beta-acetyldigoxin (author's transl)].
Original tablets of Cormelian [= 50 mg 1,4-bis[3-(3,4,5-trimethoxybenzoyl-oxy)-propyl]-perhydro-1,4-diazepine (dilazep)] and Cormelian-Digotab (= 50 mg dilazep + 0.2 mg beta-acetyl-digoxin) were produced with 3H-dilazep as prescribed in the special galenic technique. After application of a single oral dose of two tablets dilazep to 9 patients serum concentration was analysed at different times up to 24 h p.a.; the renal excretion rate of dilazep and metabolites was determined up to 48 h. Two tablets of the combination were given to 4 of these patients 4 days after application of dilazep and the corresponding analysis were repeated; in the serum of these patients the concentration of glycoside was determined by radioimmuno assay. The following results were obtained. 1. Differences in serum concentrations and renal excretion rates of dilazep and metabolites were not observed after application of the mono- and combination product. In comparison to results after oral application of pure dilazep in gelatin capsules the serum concentrations 1 h after application of Cormelian and Cormelian-Digotab were statistically significantly higher. With reference to comparable total absorption rates these results may be representative for a possibly retarded absorption rate of dilazep given as pure substance. An influence of the different galenic techniques on the intensity and direction of metabolites could not be substantiated. 2. By large dispersions of the single values high absolute and relative concentrations of beta-acetyl-digoxin were found in the serum of all the 4 patients after application of combination. Contrary to two commercial products, applied to each of 10 test persons under comparable conditions, statistically higher serum concentrations of glycoside were analysed 1 h after application of the combination. The results of these studies confirm a positive influence of the galenics on the biological availability of both the components in the combination drug Cormelian-Digotab.
D001381:Azepines / Q000378:metabolism*; D001682:Biological Availability; D004077:Digoxin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood; D004109:Dilazep / Q000008:administration & dosage / Q000378:metabolism*; D004338:Drug Combinations; D004347:Drug Interactions; D006801:Humans
D001381:Azepines; D004338:Drug Combinations; D004077:Digoxin; D004109:Dilazep
Uber die Bioverfügbarkeit der Einzelkomponenten aus einer Kombination von Dilazep und beta-Acetyl-digoxin